BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS

(marketscreener.com) NEW YORK, Nov. 10, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration regarding the company's New Biologics License Application for NurOwn for the...https://www.marketscreener.com/quote/stock/BRAINSTORM-CELL-THERAPEUT-18118014/news/BrainStorm-Cell-Therapeutics-Receives-Refusal-to-File-Letter-from-FDA-for-its-New-Biologics-License-42270947/?utm_medium=RSS&utm_content=20221110